Sage Journals: Discover world-class research

Abstract

Despite advancements in therapeutic techniques, restoring bone tissue after damage remains a challenging task. Tissue engineering or targeted drug delivery solutions aim to meet the pressing clinical demand for treatment alternatives by creating substitute materials that imitate the structural and biological characteristics of healthy tissue. Polymers derived from natural sources typically exhibit enhanced biological compatibility and bioactivity when compared to manufactured polymers. Chitosan is a unique polysaccharide derived from chitin through deacetylation, offering biodegradability, biocompatibility, and antibacterial activity. Its cationic charge sets it apart from other polymers, making it a valuable resource for various applications. Modifications such as thiolation, alkylation, acetylation, or hydrophilic group incorporation can enhance chitosan’s swelling behavior, cross-linking, adhesion, permeation, controllable drug release, enzyme inhibition, and antioxidative properties. Chitosan scaffolds possess considerable potential for utilization in several biological applications. An intriguing application is its use in the areas of drug distribution and bone tissue engineering. Due to their excellent biocompatibility and lack of toxicity, they are an optimal material for this particular usage. This article provides a comprehensive analysis of osteoporosis, including its pathophysiology, current treatment options, the utilization of natural polymers in disease management, and the potential use of chitosan scaffolds for drug delivery systems aimed at treating the condition.

Keywords

Chitosan chitosan-based scaffolds osteoporosis natural polymers nanostructures drug delivery systems bone tissue engineering

Introduction

The skeletal system is a vital component of the human body, comprising several tissues that contribute to its structure and function.¹ Approximately 60% of human bone is formed of inorganic mineral content, with hydroxyapatite being the most often recognized. The remaining 30% is comprised of an organic matrix, which is made up consisting of collagen, proteoglycan, and lipid. Additionally, bone contains approximately 10% cells and blood vessels, all of which play crucial roles in its maintenance and overall health.² The skeleton serves several crucial roles inside the human body. Firstly, it provides structural support, ensuring the integrity, and stability of the body. Additionally, it offers support to vital organs housed within its framework. Furthermore, the skeletal system serves as a reservoir for essential minerals and contributes to the creation of blood.^3,4 The complex and specialized dynamic tissues undergo continuous metabolism and remodeling throughout an individual’s lifespan in order to sustain a robust skeletal framework for various physiological processes. Bone metabolism encompasses a complex interplay of various fundamental bone cells, including osteocytes, osteoblasts, and osteoclasts, which individually or collectively play pivotal roles in maintaining the equilibrium between bone breakdown and formation.^5,6 The remodeling of bone commences with the activation of osteocytes through mechanosensory stimuli, subsequently leading to the recruitment of osteoclasts to the diseased areas of bone.⁷ In addition, the recruitment of MSCs and bone progenitors is observed, resulting in the specialization of MSCs into osteoblasts. The aforementioned process finally culminates in the mineralization of the osteoid matrix, hence facilitating the development of new bones. Altering any of these stages has the potential to result in bone metabolism disorders.⁸

Some prevalent bone related ailments are osteoporosis, osteomyelitis, Paget’s syndrome, osteosarcoma, and arthritis.⁹ Osteoporosis is a degenerative condition affecting the body’s skeleton, which leads to a reduction in bone density and degeneration of the microarchitecture of the bone tissues. This leads to heightened vulnerability to fractures and enhanced fragility of the bones.¹⁰ It is a lifelong progressive disease characterized by the gradual loss of bone mass. Osteoporotic patients commonly experience limited or moderate symptoms prior to the onset of osteoporotic fragile fractures.¹¹ The fractures give rise to a range of unfavorable outcomes, encompassing persistent discomfort, impairment, depressive symptoms, diminished standard of life, and higher mortality.¹² The worldwide incidence of osteoporosis has appeared as a significant public health concern due to the increasingly rapid aging of population. On a global scale, the occurrence of osteoporosis is estimated to affect over 200 million individuals, with approximately 9 million fractures due to fragility occurring each year.¹³ The numbers presented above depict the simultaneous increase in the older population facing a decline in their general standard of life and the rising socioeconomic burden.¹⁴ However, the existing pharmacological and surgical interventions employed for the treatment of osteoporosis are deemed inadequate. Hence, it is evident that there exists an urgent requirement and growing desire for novel pharmaceuticals targeting osteoporosis as well as nanomaterials aimed at enhancing the healing process of fragility fractures.

In modern times, there has been a discernible surge in the exploration of the application of polymers derived from naturally occurring substances for various medicinal and biological purposes.¹⁵ These applications encompass pharmaceutical delivery systems, engineering tissues, wound treatment, and packaging for food, among others.^16,17 Naturally occurring polymers encompass two main categories: protein-based and polysaccharides-based. In contrast to polysaccharides, proteins exhibit amino acids sequences that are commonly associated with cellular attachment through integrin-binding domains. In contrast, it is necessary to augment cell adhesion and osteoconductivity in polymer scaffolds through chemical surface changes, the blending of osteoconductive substances, or the inclusion of integrin-binding sequence or cell adhesive proteins. The polymers of natural origin that are frequently investigated for biomedical applications encompass chitosan, collagen, alginate, peptides, and other more compounds.^18,19 Chitosan is a widely utilized polymer in the field of medical research, ranked as the second most prevalent after cellulose. It is classified as a naturally existing amino polysaccharide.²⁰ The solubility in water of chitosan is attributed to its polycationic properties, enabling it to effectively connect to negative-charged surfaces, including mucous membranes, due to its bioadhesive nature. Consequently, it augments the adherence to the mucosal surface, thus prolonging the duration of drug molecule interaction for enhanced penetration.²¹ The compound exhibits remarkable biocompatibility and minimal toxicity owing to its molecular and structural similarities to endogenous glycosaminoglycans.²² Chitosan undergoes rapid biodegradation, resulting in the formation of nontoxic byproducts known as amino sugars, which are readily absorbed by the human body.²³ Moreover, the properties and effects of chitosan in biological systems can be altered through appropriate physical and chemical modifications of its chemical makeup.²⁴ The favorable utilization of chitosan in many practical domains can be facilitated by modifications in its molecular weight (MW), degree of deacetylation (DD), cross-linking, covalently bonded functional groups, as well as the incorporation of coordinated anion or polyanion.²⁵

A substantial amount of research has been dedicated to the investigation of chitosan-based nanostructures as potential therapeutic interventions for bone-related ailments. The objective of this review is to present a comprehensive analysis of the latest advancements in the field of pharmaceutical delivery systems based on chitosan, focusing on their application in the treatment and control of osteoporosis. The forthcoming prospects of chitosan based nanosystems are also emphasized, aiming to provide new opportunities for the development of optimal materials to aid in the cure of bone diseases.

Osteoporosis

Osteoporosis is a pathological condition affecting bone metabolism, which manifests as a prolonged decline in trabecular bone mass and an elevated vulnerability to bone fractures. The hormonal changes that occur after menopause, together with the natural process of aging, disrupt the equilibrium of bone homeostasis.^26,27 The aforementioned diseases lead to atypical bone remodeling characterized by an elevated rate of bone turnover and reduced osteogenesis activity, which eventually results in loss of bone and degeneration of the microarchitecture. The global prevalence of osteoporosis has become a significant medical and social worry owing to the increasing age of the general population. The current approach to managing osteoporosis mostly involves the administration of pharmaceutical interventions, specifically anti-resorptive medicines and anabolic agents.^28,29 Nevertheless, the utilization and effectiveness of these treatments are hindered by several factors, including the occurrence of various adverse effects and the lack of patient adherence resulting from prolonged usage.³⁰ The development of more efficacious rehabilitation techniques for osteoporosis is essential. Therapeutic approaches utilizing nanomaterials with pronounced osteogenic and osteo-conductive properties have emerged as highly intriguing possibilities in the realm of osteoporosis management.^31,32 In the past few years, there has been growing acceptance of the potential of injectable hydrogels and nanoparticles as potential materials for the treatment of osteoporosis. Extensive research has been conducted on hydrogels and drug-loaded nanoparticles as local delivery systems in order to get accurate and long-lasting drug release.³³

Bone remodeling process

In order to attain desirable therapeutic effectiveness, it is imperative to comprehend the underlying molecular processes and genetic factors that contribute to osteoporosis, together with alterations in the milieu of the bone. The pathogenesis of osteoporosis can be primarily attributed to an imbalance in the processes of osteogenesis and osteoclastogenesis.²⁸ Bone is a complex tissue that experiences continuous modelling and remodeling processes facilitated by the activation of many cell types.³⁴ Osteoclasts are derived from hematopoietic cell precursors and play a substantial part in the process of bones resorption. Conversely, osteoblasts are derived from MSCs and contribute to bone production.³⁵ Osteocytes, which are osteoblasts that have completed the process of terminal differentiation, are situated within mineralized bone and provide a crucial function in governing the temporal and spatial aspects of bone remodeling.³⁶ Bone remodeling is a complex physiological process that consists of five distinct phases: activation, resorption, reversal, creation, and termination. The activation phase primarily encompasses the initiation of the remodeling signal through the upregulation of RANKL expression in osteocytes located at locations of bone injury.²⁶ This upregulation facilitates the attraction, differentiation, and fusing osteoclast precursors that ultimately results in the development of osteoclasts. Osteocytes are accountable for the conversion of mechanical strain messages into biological impulses, which subsequently trigger the process of bone remodeling. The role of parathyroid hormone is to support the maintenance of calcium homeostasis and initiate bone remodeling through its interaction with receptors located on osteoblasts.³⁷

During the resorption phase, the recruitment of osteoclasts occurs at the site of remodeling. The osteoblast is involved in the secretion of cytokines and structural metalloproteases, which play a pivotal role in promoting osteoclastogenesis. As a consequence, there is a progression of unmineralized osteoid breakdown and the subsequent development of spots for osteoclast attachments.³⁸ During the phase of reversal, the process of bone resorption assisted by osteoclasts is concluded, and the bone undergoes preparations for osteoblast-mediated bone synthesis. This preparation involves the elimination of collagen residue by the mononuclear cells.³⁹ During the formation stage, osteoblasts release bone matrix, also known as osteoid, which is subsequently deposited at the sites of bone resorption to counterbalance the loss of bone.⁴⁰ The primary highlight of the formation phase is the maturation and specialization of osteoblast progenitor cells and the production of chemicals that facilitate bone growth, such as type I collagen, alkaline phosphatase, lipids, and proteoglycans.⁴¹ In the final stages, the process of remodeling ends when the resorbed bone is entirely replaced by freshly produced bone in an equivalent quantitative proportion (Figure 1). The process of mineralization of osteoid is the concluding stage in the bone production phase, wherein hydroxyapatite crystals undergo growth within matrix vesicles and then adhere to type I collagen. Osteoclasts undergo programmed cell death within a span of several weeks, whereas the apoptosis of osteoblasts occurs over the course of several months. The progressive acceleration of bone remodeling processes will result in a decline in bone density.^38,42

Figure 1.

The bone reconstruction process and its most common types of cells that contribute to bone remodeling. The figure shows the five phases of bone remodeling: 1. Activation step; 2. Bone resorption period; 3. Reversal period; 4. Bone formative stage; and 5. Termination phase.

Various routes facilitate bone regeneration by regaining the equilibrium between osteoblasts and osteoclasts, so promoting the production of new bones at the sites of injury. The Wnt/β-catenin signaling system is involved in various cellular determinations throughout the entire process of bone healing. Wnt signaling, facilitated by β-catenin, contributes to the restoration of bone fractures by enhancing the formation and functioning of osteoblasts.⁴⁴ The Notch signaling pathway is a ligand-receptor signaling system that facilitates cell proliferation, differentiation, their survival, and determination of cell destiny. The activation of this pathway occurs when notch ligands engage with their receptors. This is a potential route that directly stimulates bone cells known as osteoblasts, leading to bone formation.^45,46 The bone morphogenetic protein (BMP)/transforming growth factors-β (TGF-β) pathway is a significant route involved in the process of bone regeneration. Bone morphogenetic proteins (BMPs) are a member of the transforming growth factor-beta (TGF-β) class, playing a vital part in the process of osteogenesis.⁴⁷ BMPs have been shown to induce endochondral bone growth in mice. However, assessing the efficacy of BMPs in foetal and adult subjects poses challenges. BMP2 is a subject of interest within the realm of clinical research due to its demonstrated efficacy in the process of bone regeneration. The BMP2 plays a crucial role in promoting bone regeneration through its ability to stimulate MSCs and osteoblast progenitor cells, ultimately resulting in the creation of callus.^48,49 Figure 2 illustrates several more pathways that play significant roles in the mechanism of bone regeneration.

Figure 2.

Different pathways that contribute to bone regeneration by reinstating the equilibrium between the roles of osteoblasts and osteoclasts, hence promoting the production of new bone at the site of injury: (a) mitogen-activated protein kinase (MAPK) pathway regulating cellular processes like proliferation, differentiation, migration, and cell death, which are vital for bone formation,⁵⁰ (b) platelet-derived growth factor (PDGF) an external factor regulates cellular processes in the skeletal system, stimulating cell division, development, and blood vessel formation, ultimately increasing the population of MSCs,⁵¹ (c) insulin-like growth factor (IGF) pathway is crucial for osteoblast proliferation and differentiation, with IGF1 and IGF 2 being the only members with similar biological traits and expression within osteoblasts, and⁵² (d) fibroblast growth factor (FGF) pathway is crucial for bone cell formation, maintaining proliferation and differentiation of fibroblast osteoblasts, and regulating signaling pathways in osteoprogenitor cells.⁵³

Role of bone cells in bone remodeling

Bone remodeling is a dynamic process that involves the coordinated activity of three primary cell types, namely the osteoclast, osteoblast, and osteocyte. These cells are essential for the maintenance of the integrity of structure and functional properties of bone tissue. Osteoclasts are the cellular entities accountable for the process of bone resorption. MSCs are distinguished from hematopoietic stem cells and exhibit a tight relationship with macrophages and monocytes.⁵⁴ The process of osteoclastogenesis encompasses the transformation of bone marrow precursors into fully-activated osteoclasts with multiple nuclei.⁵⁵ The efficacy of this procedure is contingent upon the presence of M-CSF and RANKL. The process of osteoclastogenesis is initiated by the binding of M-CSF to its receptor, known as colony-stimulating factor-1 receptor (C-FMS).⁵⁶ This connection induces an increase in the activity of the transcription factor c-FOS, which subsequently triggers the activation of RANK expression. The activation of the receptor activator of nuclear factor kappa-B (RANK) by its ligand, RANKL, initiates a cascade of events that leads to the synthesis and release of several proteins and enzymes that facilitate the process of osteoclastogenesis.⁵⁷ The activation of the IκB kinase (IKK) complex is initiated by the process of phosphorylation of κB-inducing kinase (NIK). The IKK complex facilitates the activation of NF-κB by the process of ubiquitination and subsequent destruction of its suppressor molecule, IκB. The transcription factor NF-κB has the ability to initiate the activation of NFATc1, which subsequently undergoes a process of self-amplification to activate genes associated with osteoclastogenesis.^58,59

Osteoclasts, which exhibit a morphology resembling that of jellyfish, adhere to bone surfaces and establish a sealing zone. The resorptive activity is subject to the impact of cathepsin K. Osteoblasts, which are accountable for the process of bone production, are derived from MSCs.⁶⁰ The Wnt/β-catenin pathway is of significant importance in the regulation of osteoblastic development. Wnt inhibitors like as Dkk-1 and sclerostin exert a negative regulatory effect on this pathway.⁶¹ Three critical transcription factors implicated in the process of osteoblast development include Runx2, osterix, and β-catenin.⁶² Mature osteoblasts are responsible for the secretion of an organic matrix, which subsequently undergoes mineralization to facilitate the formation of bone tissue. The differentiation process of osteoblasts plays a crucial role in determining the rate and efficiency of bone production.⁶³ Osteocytes, comprising more than 90% of cellular components in bone, are specialized osteoblasts that play a crucial role in the process of bone remodeling. These cells exhibit resemblances to neural cells and facilitate the transmission of mechanical loading signals within the bone.⁶⁴ Osteocytes demonstrate the expression of factors implicated in phosphate metabolism, hence indicating the possibility of matrix mineralization. Cytokines such as Dkk1, sclerostin, RANKL, and OPG are released by these cells, and they play a critical part in retaining bone equilibrium by impeding the differentiation of osteoblasts and the creation of bone.^65,66

Nanomaterials in treatment of osteoporosis

The utilization of nanomaterials in the field of bone regeneration has shown a substantial increase in recent times. The term “nanomaterial” refers to a substance that possesses a dimension inside the nanometer scale, often ranging from approximately 1 to 100 nm. The characteristics of nanomaterials undergo significant alterations as a consequence of the higher surface-to-volume ratio.⁶⁷ Nanoparticles have demonstrated significant potential as precise and effective vehicles for medication delivery. Nanomaterials have the potential to be utilized in the development of drug delivery systems that specifically target bones, enabling the loading of therapeutic compounds such as medicines and vesicles.¹² Furthermore, it is possible to alter them in order to exhibit intrinsic therapeutic properties. Pharmacological intervention is a prevalent therapeutic approach for the management of osteoporosis. For an extended period, this therapeutic approach has encountered challenges related to the distribution of medication to unintended targets and the occurrence of unfavorable consequences. In order to tackle these concerns, scientists have been attempting to fabricate nanoparticles possessing the capacity for precise targeting, thereby serving as efficacious medication delivery systems. However, the issue of off-target delivery continues to be a significant constraint that hinders the broader implementation.⁶⁸ There exist two approaches for achieving bone-targeting functionality: a strong affinity for hydroxyapatite, exemplified by bisphosphonates and oligopeptides, or a selectivity towards cells associated with bone. The distinctive P–C–P bond found in bisphosphonates, combined with the carboxyl group present in oligopeptides, imparts these molecules with a high selectivity for the apatite found in the tissues of bone.⁶⁹ Table 1 presents an overview of the application of nanoparticles in the therapeutic management of osteoporosis.

Table 1.

Nanomaterials employed in the administration of medicines for osteoporosis.

Nanomaterial	Therapeutic agent	Characteristics	Remarks	Ref.
Chitosan NPs	Alendronate	Biocompatible, pH responsive, and storage stable	The osteogenic differentiation of hA-MSCs has significantly improved, making them a promising material for bone tissue engineering scaffolds.	Moradikhah et al.⁷⁰
Chitosan NPs	Raloxifene hydrochloride	Storage stable, biocompatible, and sustained release	Raloxifene-loaded chitosan NPs could be a promising nanoparticulate drug delivery system for treating osteoporosis.	Saini et al.⁷¹
Chitosan NPs	Risedronate	Storage stable, biocompatible, and sustained release	Risedronate-loaded chitosan NPs has shown promising outcomes in facilitating bone bridging and treating osteoporosis effectively.	Santhosh et al.⁷²
Chitosan-hydroxyapatite microspheres	Resveratrol	Biocompatible, sustained release, and anti-inflammatory	Optimized microspheres showed enhanced entochondrostosis and bone regeneration, suggesting potential as multifunctional fillers for fracture treatment.	Li et al.⁷³
PLGA NPs	MSC-Sec	Biodegradable, sustained release, and specific targeting	NPs loaded with MSC-Sec accumulate in bone, inhibit osteoclast differentiation, and promote osteogenic proliferation.	Zhang et al.⁷⁴
Hydroxyapatite NPs	Salmon calcitonin	High drug loading, highly permeable, and sustained release	Sublingual NPs increased bone mass, mechanical strength, and decreased erosion in ovariectomized osteoporosis, suggesting targeted bone delivery as a non-invasive alternative.	Kotak and Devarajan⁷⁵
HA-PBA nanocarriers	Adenosine	High drug loading, control release, biocompatible, and specific targeting	The study suggests that a bone-targeting nanocarrier could be a potential therapeutic strategy for treating osteoporosis and promoting bone health through systemic administration of adenosine.	Hoque et al.⁷⁶
SPIONs	MSCs	Superparamagnetic	Facilitating the attachment and proliferation of BMSCs, and augmenting the osteogenic properties.	Liu et al.⁷⁷
Mesoporous silica NPs	Osteostatin and SOST siRNA	High drug loading, biocompatible, and co-delivery	The combination of SOST siRNA and osteogenic peptide enhanced osteogenic differentiation markers, suggesting potential for intrabone marrow injection as a gene therapy platform for osteoporosis treatment.	Mora-Raimundo et al.⁷⁸

In contrast to traditional pharmacological interventions, gene therapy via RNA interference (RNAi) is an innovative strategy in the management of systemic osteoporosis. RNAi is an intrinsic biological mechanism that selectively destroys certain messenger RNA (mRNA) molecules, resulting in the subsequent reduction of the related proteins. The application of RNAi to suppress genes associated with osteoporosis is a potentially effective approach for the systemic treatment of this condition. RNAi treatments, albeit promising, face limitations such as shorter half-lives, rapid degradation rates, and inadequate penetration capabilities. The use of nanoparticles has been employed as a strategy to tackle these challenges, primarily focusing on safeguarding and transporting nucleic acid molecules.^79,80 The field of nanomedicine has seen significant interest in the utilization of nanoparticles of mesoporous silica (MSNs). The great loading capacity of MSNs can be attributed to their mesoporous structure, which provides a huge surface area, as well as their good biocompatible and biodegradable properties. A novel delivery strategy based on MSN has been recently created for the efficient delivery of small interfering RNAs (siRNAs) specifically intended for targeting the SOST gene. The gene in question is responsible for the production of sclerostin, a protein that functions as a suppressor of osteogenesis. The use of a polyethylenimine coating to the MSN-based system of administration enhances its potential to simultaneously distribute SOST siRNA and osteostatin, an osteogenic peptide. The introduction of the MSN nanomaterials into the tissue of bones resulted in an increase in the expression of genes associated with osteogenesis, leading to enhancements in bone structure and alleviation of osteoporosis.⁷⁸

Several types of nanoparticles have inherent therapeutic properties, including the ability to suppress the formation of osteoclasts or enhance the development of fresh bone cells, known as osteogenesis. The therapeutic efficacy of inorganic nanoparticles in promoting bone regeneration in individuals with osteoporosis has been proven. The core-shell structure of HA-Iron oxide nanoparticles has been shown to possess dual capabilities in facilitating osteogenesis and suppressing osteoclastogenesis.⁸¹ Nitric oxide (NO) plays a significant role in the process of bone regeneration. It has a substantial role in facilitating osteogenesis and mitigating the effects of osteoporosis. Nevertheless, the utilization of NO poses certain difficulties due to its limited duration of activity and extensive range of diffusion, spanning from 40 to 200 micrometers. Extensive research has been conducted on the subject of light-controllable release of NO.⁸² In addition to their role as carriers for delivering pharmaceuticals and regulators with intrinsic anti-osteoporosis characteristics, tiny particles also serve as boosters in scaffolds for osteoporotic bone tissue engineering or injectable form of hydrogels for drug loading. This is achieved through a synergistic mechanism that promotes osteogenesis by enhancing physiochemical characteristics of these substances.⁷⁰

The utilization of nanoparticles in the context of osteoporosis presents several potential benefits, including convenient application, adaptability, rapidity, efficacy, adjustable multifunctionality, and limited invasiveness. To begin with, nanoparticles possess the inherent capability to undergo facile modifications or seamless integration with biological components, including growth factors. The aforementioned phenomenon can be ascribed to the inherent chemical features of the substances, which facilitate the adherence of cells and the development of stem cells. Moreover, the incorporation of inorganic nanomaterials as fillers has been shown to effectively manipulate and augment the mechanical characteristics of tissue engineering materials, including hydrogels and scaffolds. Nanostructures are highly suitable for the purpose of precisely administering anti-osteoporotic medicines and nucleic acids, hence promoting the repair of bone tissue affected by osteoporosis.⁸³ Notwithstanding these benefits, it is imperative to acknowledge the challenges pertaining to the implementation of nanomaterials in real contexts. To begin with, it is important to note that nanoparticles exhibit cytotoxic properties.⁸⁴ Therefore, it is necessary to conduct further research for the purpose to gain a better comprehension of the biological safety of nanoparticles in the context of osteoporotic bone regeneration, with a specific focus on their suitability for long-term therapeutic applications. Recently, polymers have garnered significant acceptance among scholars owing to their exceptional attributes such as biocompatibility, bifunctionality, and biodegradability. The aforementioned characteristics render it well-suited for various medical applications, such as biomedicine, pharmaceuticals, the engineering of tissues, and delivery systems for drugs.

Polymers in osteoporosis management

There has been a noticeable surge in interest surrounding the application of naturally occurring polymers in many medical and biological contexts in contemporary times. These applications encompass systems for delivering drugs, engineering tissues, wound treatment, among others.⁸⁵ Naturally occurring polymers can exist in two forms: protein-based or polysaccharide-based. In contrast to polysaccharides, proteins exhibit amino acid sequences which are commonly linked to cellular attachment through integrin-binding domains. In contrast, the augmentation of cell adhesion and osteoconductivity inside polysaccharide scaffolds necessitates the implementation of chemical surface changes, the amalgamation with osteoconductive substances, or the integration of integrin-binding sequences or cell adhesion proteins. Polymeric materials of natural origin that are frequently investigated for biomedical applications encompass chitosan, collagen, alginate, and peptides.⁸⁶ Among the various types of naturally occurring polymers, polysaccharides are particularly prevalent due to their intricate architectures and inherent propensity to form supramolecular network.³³ Some of the merits and de-merits of natural polymers are presented in Table 2. The presence of chemically active groups, such as hydroxyl, carboxylic acids, and amines, within the molecular composition of polysaccharides can confer several advantageous properties in vivo. These include an extended half-life within the organism, the ability to facilitate cellular proliferation, and the capacity to form hydrogels with minimal elicitation of inflammatory or immunological reactions.⁸⁷ This review aims to explore the potential of chitosan as a material for the management of osteoporosis.

Table 2.

Merits and demerits of naturally occurring polymers.

Aspects	Merits	Demerits
Biodegradability	Natural polymers are widely adopted due to their excellent biodegradable properties which minimizes long-term risks.	The long-term effectiveness of the implanted scaffold may be compromised.
Biocompatibility	Natural polymers are easily recognized and accepted by the human body due to their inherent characteristics of high bioactivity and biocompatibility.	The biocompatibility of these polymers can be influenced by their processing and procurement.
The facilitation of cellular proliferation	They can provide conductive environment for cell proliferation, cell adhesion, and differentiation.	Limited control over the cellular proliferation.
Ease of modification	Specific properties can be enhanced with the incorporation of bioactive molecules.	The therapeutic efficacy of a medication delivery system may be impacted by batch-to- batch variations.
Osteoconductivity	These materials demonstrate osteoconductive characteristics that can promote the bone tissues ingrowth.	Weak mechanical strength and stability can effect osteoconductive properties of many naturally occurring polymers.
Cost effectiveness	Natural polymers can be cost-effective due to their natural source.	Processing and purification of these polymers can significantly increase the overall cost.

Chitosan

Chitosan, a type of carbohydrate bio polymer, has garnered significant attention from researchers worldwide, recognized as a well-researched natural biopolymer with significant potential. Chitosan is a polysaccharide derived from chitin, which is a biopolymer occurring naturally in shells and fungus, and is obtained through the process of deacetylation.⁸⁸ The significant level of interest in chitosan stems from its exceptional attributes of high biocompatibility, biodegradability, biological activity, and low toxicity. Figure 3 encompasses a variety of distinct physical, biological, and chemical properties of chitosan. The potential applications of this substance in many biomedical contexts includes its utilization as a vehicle for drug delivery, incorporation into wound care products, and integration with implant materials. Chitosan is recognized as a substance that facilitates the regenerative processes of both hard and soft connective tissues.⁸⁹ It has demonstrated independent and synergistic antibacterial properties, establishing its status as an antibacterial biopolymer. Due to its inherent characteristics and facile nanoparticle formation, the material in question can be utilized for the fabrication of diverse structures such as microfibers, beads, membranes, gel-like substances, sponge-like architectures, and scaffolds. The utilization of this material as the primary scaffold component appears to be very intriguing.⁹⁰ Extensive study has been conducted on the application of chitosan based scaffolds in the field of tissue engineering for bones. The primary objective of a scaffold is to facilitate the establishment and advancement of tissue ingrowth by offering a supportive framework and conducive surroundings. Ultimately, the scaffold is intended to degrade while simultaneously facilitating the substitution of new healthy tissues.⁹¹

Figure 3.

Different properties and derivatives of chitosan.

This biopolymer exhibits notable appeal as a bone scaffold due to its ability to facilitate the generation of hydroxyapatite, and it also promotes the adhesion and development of osteoblast cells. Numerous scaffolds have undergone extensive testing, employing a diverse range of fillers in their fabrication. Notable examples include carbon nanotubes, titanium oxide, polypyrrole, and zirconium nanomaterials.^92,93 Without a doubt, calcium phosphates, particularly hydroxyapatite, are the most often employed fillers in chitosan composites for the purpose of bone regeneration. The extensive utilization of this substance can be attributed to the reason that hydroxyapatite contains the primary constituent of human skeletal structure.⁹⁴ As a result of the growing demand for biomaterials, scaffolds must possess the ability to release pharmaceutical agents along with their fundamental characteristics. Bisphosphonates are the pharmacological class of medications most frequently employed in the treatment of osteoporosis, a prevalent skeletal disorder.⁹⁵ Drug release of various categories of pharmaceuticals from chitosan scaffolds has the potential to facilitate accelerated recovery of patients following surgical procedures. Nevertheless, it is imperative that the administration of the medicine be limited to modest dosages owing to its pronounced toxicity at higher dosages.⁹⁶ Furthermore, the physical and chemical characteristics of chitosan are influenced by several parameters, such as its degree of deacetylation and its molecular weight. The structural flexibility of chitosan is a significant characteristic attributed to the existence of active hydroxyl and amino groups within its molecular chain. The flexibility for chemical alteration of each repeating unit is attributed to the existence of two hydroxyl groups at C-3 and C-6 positions and an amine group at the C-2 position.²⁴

The properties and effects of chitosan in living systems can be altered through appropriate physical and chemical modifications in its chemical composition. The favorable utilization of chitosan can be achieved by making modifications to its molecular weight, degree of deacetylation, cross-linking, covalently bonded active groups and moieties, as well as including coordinated anions or polyanions. These modifications can be applied in many practical domains where chitosan is implemented. By incorporating minor chemical groups into the structure of chitosan, such as alkyl groups like hydroxyl-propyl or carboxy-methyl groups, the solubility of chitosan can be significantly enhanced.⁹⁷ The cationic feature can be reverted by sulfonation, resulting in the introduction of an anionic characteristic. This modification leads to improved water solubility, enhanced paste flow, a higher water reducing ratio, and anticoagulation properties. The mechanical durability of the particles is enhanced by increasing the crosslinking of CS, for example, through the use of anions, dextran, formaldehyde, and glutaraldehyde. Highly cross-linked particles exhibit reduced swelling, decreased infiltration of water into their interior, and limited diffusion of drugs from their exterior. Crosslinking has the ability to decelerate the release of drugs and hinder sudden release.⁹⁸ The mucoadhesive characteristics can be enhanced by trimethylating the main amino groups of chitosan and by PEGylation or attachment of SH groups that interact with the cysteine rich area of the mucous glycoprotein. Enhancement of mucoadhesive properties can also be achieved through the creation of complexes including polyvalent anionic medicines, excipients, and polyvalent inorganic anions (Table 3).⁹⁹

Table 3.

Typical modification of chitosan through different chemical procedures.

Reactions scheme	Chemical procedure	Ref.
	Thiolation of chitosan via carbodiimide mediated reactions	Luo et al.¹⁰⁰
	Thiolation of chitosan with reactive ligands	Al Harthi et al.¹⁰¹
	Thiolation via reactive ligands followed by reduction	Cheng et al.¹⁰²
	Alkylation of chitosan	Akopova et al.¹⁰³
	Acylation of chitosan	Merchant et al.¹⁰⁴
	Incorporation of hydrophilic group into chitosan	Rajabi et al.¹⁰⁵

Chitosan may be effectively cross-linked using glutaraldehyde, which significantly improves its ability to rapidly create a hydrogel without the need for any potentially dangerous chemicals. The gelation characteristics of chitosan can be enhanced through thiolation. Thiolation significantly amplifies the permeability effect, sometimes more than 30 times. Trimethyl chitosan (TMC) is soluble across all pH levels and has been observed to decrease trans-epithelial electric resistivity by 25%–85%. TMC is an effective permeation enhancer due to its ability to disrupt tight junctions. Additionally, it enhances the paracellular transportation of the medications.¹⁰⁶ Despite having numerous functional qualities, chitosan is limited by its significant hydrophilicity, limited ductility, considerable swelling, and thermal instability. An important constraint to its usage is its low solubility. Chitosan is not soluble at the normal pH level found in the body (pH 7.4) and does not effectively improve absorption, which hinders its use in biomedical applications. Enhancing the solubility of chitosan is a vital aspect for safe utilization across many applications.⁹⁸ In the past few years, there has been a growing interest in the chemical derivatives of chitosan due to their enhanced capabilities in comparison to the unmodified form. These derivatives offer benefits in terms of the ability to dissolve, gel-forming properties, ability to design water-resistant derivatives with amphiphilic character. Over the years, many types of chitosan derivatives products have been created to meet the specific needs of diverse biological applications.¹⁰⁷

Synthesis of chitosan scaffolds

Chitosan scaffolds used in the management of bone diseases are designed to replicate the complex and ever-changing bone matrix found in living organisms. Hence, the selection of the construction procedure significantly influences the physiochemical and biological aspects of the scaffolds.¹⁰⁸ Chitosan scaffolds are fabricated employing a diverse range of processes. Several methods can be employed for the purpose of achieving certain outcomes. These methods include selective laser sintering, electrospinning, solvent casting, and particle leaching, freeze-drying, inkjet printing, 3D Bio-plotting, gas foaming, stereolithography, etc. (Figure 4).^109,110 Table 4 details the specific benefits and drawbacks of each technique. Lyophilization is the prevailing methodology employed for the production of chitosan scaffolds among various other methods. When the chitosan solution is subjected to freezing, ice crystals are formed through the process of phase separation. Upon sublimation, the crystals vacate the original volume they occupied, resulting in the creation of pores. Achieving precise control over the temperature is imperative for the successful implementation of this technique.¹¹¹ One of the drawbacks associated with this phenomenon is the potential collapse of the pore’s structures in the absence of temperature regulation. The growth of bigger pores is a potential outcome, and the selection of solvents is constrained. Solvent-exchange/phase-separation, a technique reliant on the gelation of a solution through the introduction of an alkaline solution below its gelation threshold, can be employed. By employing these methodologies, it is possible to fabricate 3D scaffolds with diverse geometries. However, a significant drawback of these approaches is the inadequate mechanical robustness. The salt leaching technique entails the integration of porogens, such as NaCl, of specific dimensions into a chitosan matrix. Subsequently, the salt particles are removed through a series of water leaching processes, leading to the creation of porous CS scaffolds.¹¹²

Figure 4.

This diagram illustrates the prevalent fabrication techniques employed in the production of chitosan-based scaffolds, including the use of freeze-drying, freeze gelation, salt leaching, electrospinning, and 3-D printing.

Table 4.

Merits and demerits of various scaffolding fabrication techniques.

Technique	Benefits	Drawbacks	Ref.
Selective laser sintering	• Low operating cost technique • Provides control and high precise complex scaffold structure • High porosity and mechanical strength • No need for post-processing.	• High operating temperature required • Materials stable at high temperature are used. • Challenges in removal of excess trapped material • Requires post-sinter stage.	Yuan et al.¹¹³
Electrospinning	• Applicable for usage in large scale production • Controls nano and microscale slender fiber dimensions • Produces uniform blends with nanoscale fibers • Prepare polymers with exceptional tensile strengths	• 3D scaffold production limitations • Inadequate regulation of pore size and shape • Utilization different solvents for biomaterials can cause cytotoxicity	Kopp et al.¹¹⁴
Solvent casting and particle Leaching	• Adjustable scaffold porosity and pores size • High porosity and 3D cell structure formation • Easy production	• Harmful solvents cause denaturation • Molecules lose bio-inductive ability • Thin membranes complicate degradation process.	Chocholata et al.¹¹⁵
Freeze-drying	• Increases porosities • Creates modifiable scaffolds • Enhances connection between porous structure and extracellular matrix.	• Energy-demanding and time-consuming process • Use of cytotoxic solvents • Causes tissue shrinkage	Perez-Puyana et al.¹¹⁶
Inkjet printing	• Fast, controllable procedure for precise droplet size • A considerable quantity of biomaterial is accessible • Affordable, high resolution, efficient processing, consistent results	• Insufficient droplet placement and size • Requires low viscosity	Pati et al.¹¹⁷
3D Bio-plotting	• Effective interconnection of scaffold pore size • Utilization of large biomolecules and biomaterials	• Low mechanical strength of scaffold • Slow operation challenges	Yuan et al.¹¹⁸
Gas foaming	• Organic solvents’ non-flammability • Cost-effective processing • CO₂ acts as porogen gas	• Process not suitable for hydrophilic materials • Low solubility of used CO₂	Chocholata et al.¹¹⁵
Stereolithography	• Offers exceptional precision and superior quality • Forms intricate 3D arrangement with consistent interconnections and pore structure • Eliminates surplus photopolymer and liquid through heat • Preserves growth factors and cell patterning	• Maintains scaffold strength through post-polymerization • Requires low-range photo-polymerization materials • Requires large monomer quantity and structural support • Utilizes costly materials	Creff et al.¹¹⁹

The electrospinning technique involves the conversion of a polymer solution into nanofibrous mats through the application of a strong electric force. The process of electrospinning operates based on a fundamental principle whereby the application of an electric charge surpasses the surface tension of the polymer solution, leading to the accumulation of a charged polymer jet on a metallic collector. The system consists of three primary components: a high direct current (DC) voltage source, a spinneret, and grounded collectors. The utilization of this adaptable methodology facilitates the generation of fibers at both the nano and micro scales.^120,121 The MSN/CS nanofibrous membranes scaffolds were manufactured by Li et al.¹²² using the electrospinning approach. The findings of their study demonstrated an increase in tensile strength, water retention capabilities, and promotion of osteoblast growth. Additionally, it was revealed that the utilization of electrospun MSN/CS tiny fibers as scaffolds is more advantageous compared to using solely electrospun CS nanofibers. This preference is attributed to the superior microenvironment offered by the former, which promotes cellular growth and emulates the extracellular matrix (ECM). Biomaterials present significant benefits in comparison to typical metallic implants with regards to cellular processes such as adhesion of cells, propagating, differentiation, proliferation, and others. The efficacy of scaffolds is contingent upon the physicochemical and biological characteristics of the constituent components. The scaffolds must possess a range of qualities that are appropriate for use in bone tissue engineering applications. The key factors to consider in this context are as enlisted in Figure 5. The properties and applications of scaffolds in bone tissue engineering (BTE) can be enhanced by adjusting these parameters through the incorporation of other polymers and ceramics into chitosan.

Figure 5.

Chitosan scaffolds properties including porosity, water retention ability, protein adsorption, biomineralization, and biodegradation.

Mechanism underlying the release of drugs from chitosan-based scaffolds

The release of pharmaceuticals from CS-based scaffolds can be achieved through four separate mechanisms, namely diffusion, erosion, swelling, and stimulus-embedded systems (Figure 6). Diffusion-controlled release systems regulate drug release through solvent penetration or diffusion. They can be matrix or reservoir, with the drug enclosed within a polymeric membrane.¹²³ The drug core can be liquid or solid, and the membrane can be microporous or nonporous. A saturated drug core ensures consistent drug molecule movement through the membrane, as the force driving movement remains constant. High water solubility can affect the release of a drug due to the challenge of maintaining a saturated state. Matrix systems dissolve or disseminate drug within a polymer device, with the rate of release decreasing over time due to concentration gradients.¹²⁴ The release profile of diffusion-controlled systems is significantly influenced by the properties of the drug, such as such as physical size, loading level, diffusivity in the matrix phase, and solubility in the matrix. The drug release profile is also influenced by various parameters, including the geometry of the scaffold, which impacts the path length and accessible surface area for diffusion, as well as the water content and composition of the scaffold.¹²⁵ Samaneh and Saeed reported a chitosan-based scaffold for bone repair.¹²⁶ The scaffolds were successful in loading celecoxib, a model drug, due to their large surface area. The drug showed a biphasic release pattern, with a small initial burst followed by a persistent release lasting up to 14 days. However, an increase of hydroxyapatite content in the scaffold composition reduced the drug release percentage.

Figure 6.

The mechanism underlying the controlled release of medicines from chitosan scaffolds. Chitosan exhibits promising potential as a drug/gene delivery system owing to its highly regarded biological, physical, and chemical characteristics. The release of pharmaceuticals from scaffold based on controlled substances primarily occurs through many processes.

Swelling-controlled systems utilize physical principles such as osmosis and swelling to control the release of bioactive components. The process begins with water-induced swelling of the polymeric structure, where the penetrating solvent interacts with the drug and polymer matrix, compensating for interactions between the drug and polymer matrix.^126,127 Most swelling-controlled systems are hydrogels, where the drug is contained in its dry state. When water is present, the hydrogel undergoes swelling, reducing resistance to drug solute diffusion. The release rate is primarily determined by the polymer’s swelling rate, which is influenced by crosslink density and hydrophilicity. Protein delivery can be slowed down by the ionic contact and chain entanglement that occur between the protein and the matrix.¹²⁸ Gull et al.,¹²⁹ successfully synthesized a hydrogel system with multiple response properties by employing chitosan and polyvinyl pyrrolidone. The manipulation of the concentration of tetraethyl orthosilicate, a cleavable cross-linker, allowed for the regulation of lidocaine release. This control was attributed to the delivery mechanism that is governed by swelling.¹²⁹

The erosion process of drug-loaded scaffolds is characterized by the depletion of material resulting from the detachment of monomer and oligomers from the polymer matrix. Erosion-based delivery is governed by chemical reactions that take place within the polymer matrix. Possible reactions encompass (1) the enzymatic or hydrolytic destruction of polymer chains attached to the main structure, (2) either irreversible or reversible reactions between a drug and the polymer that can be released, (3) erosion of the surface, and (4) decomposition of the entire bulk material.¹³⁰ Surface erosion can occur when the rate of water entering the polymer is significantly slower than the rate of bond hydrolysis. However, surface erosion exclusively takes place in enzymatic degrading systems when the rate of enzyme transport into the gel is slower than the rate of enzymatic degradation, due to the naturally high water content of hydrogels. In erosion, the rate-determining step is the chemical processes, which govern the overall rate of drug release. Gentile et al.¹³¹ developed a chitosan-based scaffold with localized controlled-release properties to promote bone repair. The release of simvastatin showed an initial lag phase, followed by a rapid release phase with approximately 40% release, and then a linear increase over 10–28 days. The release of drug from scaffold follows a sigmoidal pattern, which corresponds to the degradation time-profile of the polymer. This indicates that the release of drug is controlled by the degradation of the polymer.

Stimulus-responsive long-term drug release techniques are sophisticated environment sensitive processes capable of responding to various biological stimuli, including pH, ATP, redox, enzymes and glucose as well as physical stimuli including light, temperature, magnetic forces, ultrasounds, and electricity.¹³² The researchers Zhao et al.¹³³ successfully fabricated a scaffold that exhibits pH-responsive behavior, undergoing self-assembly at a pH of 7.5. The synthesis of the hybrid hydrogel system involved the combination of carboxymethyl with amorphous calcium phosphate, resulting in the formation of CMC-ACP hydrogels. The CMC-ACP hydrogels exhibited a notable enhancement in the effectiveness and advancement of BMP9-induced osteogenesis in vivo, while simultaneously inhibiting bone resorption during an extended period of ectopic presence.

Drug delivery systems are utilized to transport a diverse array of pharmaceutical substances to specific areas of absorption, hence enhancing the pharmacological efficacy of the medications. In addition, they effectively address challenges such as hydrophobicity, limited solubility, inadequate bioavailability, drug accumulation, and absence of selectivity.¹³⁴ The positively charged characteristics of chitosan enable various applications such as regulated drug release, muco-adhesion, on-site gelation, transfection, permeation improvement, and inhibition of efflux pumps. The aforementioned qualities collectively establish chitosan based scaffolds as a promising candidate for the targeted and regulated delivery of therapeutic chemicals to the site of a defect. The drug release profile can be modified by various factors, including the loading strategy, the matrix’s degradation capacity, and the precise amount of the pharmaceutical.¹³⁵ The local delivery of drugs through scaffolds has several advantages over systemic delivery, including a reduction in adverse effects and the possibility of overdose. Moreover, this methodology facilitates the enhanced and prolonged delivery of the pharmaceutical agent to the intended site, hence ensuring optimal concentration levels at the desired spot during the entirety of the healing process. Several methodologies have been devised to provide certain pharmaceuticals and bioactive compounds via chitosan-based scaffolds, with the aim of augmenting the process of bone repair.¹³⁶

Osteoporosis treatment using chitosan-based scaffolds

Osteoporosis is a skeletal condition characterized by an elevated susceptibility to severe fractures of the spine, hips, and wrists, resulting in substantial morbidity and mortality. The osteoporosis illness encompasses various factors, such as the process of aging, inadequate calcium intake, diminished testosterone levels, and genetic susceptibility.⁷² The prevalence of osteoporosis condition is on the rise within the senior population. The careful consideration and utilization of suitable methodologies at distinct phases of the osteoporosis condition are imperative for the efficient therapy and administration of the ailment. In order to address this illness, various conventional therapies have been utilized, including the use of anabolic drugs such as parathormone and its counterparts, as well as antiresorptive therapy.¹³⁷ While the objectives of these therapies align in terms of reducing bone fractures and maintaining bone integrity, it is important to note that they all face significant challenges related to bioavailability. Drug delivery systems present a promising avenue for achieving enhanced and optimal therapeutic outcomes through the utilization of convenient formulations that offer improved oral bioavailability or enhanced patient compliance.

Oral methods of drug delivery have limited bioavailability and increased instability, hence significantly reducing the effectiveness of formulations that aim to adhere to cells or undergo oral absorption. However, it is imperative for an oral medication formulation to successfully traverse digestive barriers and attach to the brush boundary of the intestinal mucosa. Subsequently, translocated particles might be absorbed by intestinal cells through intracellular absorption, paracellular uptake mechanism, or phagocytic uptake facilitated by intestinal macrophages. Chitosan-based nanoparticles exhibit considerable potential as oral drug delivery systems within the realm of polymeric nanomaterials. This is primarily attributed to their capacity to induce the opening of closed junctions among cells in the intestinal epithelium, hence facilitating the paracellular transfer of medicines.¹³⁸ Risedronate sodium, a bisphosphonate molecule containing nitrogen, is widely regarded as an effective pharmaceutical agent for enhancing bone strength and impeding the progression of osteoporosis. Regrettably, the bioavailability of the substance is documented to be below 1% upon oral ingestion. Numerous formulations have been proposed as a means of addressing this constraint.^139,140 Chitosan possesses an inherent positive charge, while risedronate exhibits a negative charge. Therefore, the formation of chitosan nanoparticles can be achieved by the ionic gelation technique, employing tripolyphosphate (TPP) as a cross-linker for the purpose of encapsulating the pharmacological agent within the chitosan nanoparticles. According to molecular modeling investigations and in vivo research, it has been observed that nanoparticles composed of risedronate-chitosan has the ability to selectively target and inhibit human farnesyl diphosphate synthase, a key enzyme in the mevalonate pathway. The formulation’s potential impact involves the inhibition of osteoclastogenesis and the subsequent prevention of bone resorption, hence promoting bone regeneration and augmenting bone density (Figure 7).⁷²

Figure 7.

Various modified forms of chitosan are used for bone repair.

In order to enhance the pharmaceutical formulation of alendronate sodium, a bisphosphonate prescription, it was encapsulated in chitosan. This approach demonstrated the required therapeutic effect and achieved prolonged release of the drug. These features offer a means to mitigate the negative consequences of alendronate sodium following its oral intake.¹⁴² Wu et al.¹⁴³ constructed a microsphere delivery system based on chitosan for controlled alendronate release and bone tissue development. The results indicated that chitosan-based scaffolds had better degradation properties, mechanical strength, controlled release, and improved osteogenic differentiation of adipose-derived stem cells by increasing calcium deposition and alkaline phosphate activity. The in vivo trial demonstrated greater efficacy of the scaffolds than autografts in fully restoring major bone defects within a period of 8 weeks, indicating their potential for localized delivery and bone regeneration (Figure 8). Raloxifene hydrochloride exhibits a limited oral bioavailability of 2%. This substance functions as an agonist for estrogen in bone tissue, effectively preventing the degeneration of vertebral bone by suppressing the function of cytokines that promote bone resorption. The bioavailability of raloxifene could be increased by encapsulating it in chitosan nanostructures. The in-vitro release investigation demonstrated an immediate and rapid release of the medication, which was subsequently followed by a gradual and prolonged release. An animal investigation shown that the plasma concentration of the medication was greater following intranasal delivery of nanoparticles compared to oral administration. The observed phenomenon can be attributed to the absorption of raloxifene hydrochloride through the nasal mucosa, facilitated by the mucoadhesive nature of chitosan nanoparticles. Hence, the administration of raloxifene chitosan NPs through the nasal route has great potential as a method for treating osteoporosis.^71,144

Figure 8.

(a) Illustration demonstrates the preparation of chitosan-based scaffolds for large bone defects in a rabbit model. (b) X-ray analysis showed how bones regenerate at different time points after the implantation surgery. While some new bone formed in the control group, the bone did not fully heal. In the autograft group, the use of autologous orthotopic transplantation resulted in complete healing of the radius breaks within 8 weeks. In the chitosan (0%)-implanted group, there was clear new bone formation at week 8. However, there were few bone fracture lines observed, and the bone marrow cavities did not become interconnected. The chitosan (10%)-implanted group experienced the healing of bone defects and the formation of new bone between 4 and 8 weeks. (c) The semi-quantitative analysis showed that new bone formation was significantly higher in the chitosan (10%) group compared to the chitosan 0% group.

A chitosan-zeolite scaffold that is compatible with living organisms was created, followed by the absorption of the medicine used to treat osteoporosis.⁹⁶ Evidence demonstrated that the zeolite is uniformly dispersed across the entirety of the scaffold, leading to a notable influence on the consistent absorption and release of the medication from materials that could potentially be used in bone tissue creation. The zeolite scaffolds exhibited a drug retention capacity that was nearly double that of the hydroxyapatite scaffolds. The reason for this is that hydroxyapatite exhibits greater agglomeration, while zeolites include holes that allow for drug permeation.⁹⁶ Recently, Zhang et al.,¹⁴⁵ combined melatonin (MT) with Chitosan and tri-block co-polymer made of poly (l-lactide) (PLA) and aniline pentamer (AP) in sequence as PLA-b-AP-b-PLA (PAP) to enhance the anti osteoporetic activity of melatonin. They prepared nanofibers and hydrogels formulations containing MT and chitosan to evaluate the effect of MT on MC3T3-E1 osteogenesis and mineralization. The findings demonstrated that chitosan@PAP nanospheres loaded with MT had beneficial osteogenic properties, both in laboratory settings and in living organisms, offering a viable approach for bone regeneration in individuals with osteoporosis. A biocompatible transdermal gel containing Risedronate (RS)-chitosan nanoparticles have been recently investigated for osteoporosis. The ex vivo Franz diffusion and in vitro cell uptake and distribution assays demonstrated significant cellular absorption and distribution, with a noticeable penetration of over 70% of the released drug in the mouse epidermal tissue. The research findings indicate that the prepared biodegradable chitosan-RS nanoparticles containing gel has the potential for treating osteoporosis and pain in clinical settings through passive targeting.¹⁴⁶ Extensive research has been conducted on the application of chitosan-β-glycerophosphate gels within the realm of biology, particularly for their potential in delivering medications that can be broken down by bacteria in the human colon. Chitosan-β-glycerophosphate hydrogels can function as a drug reservoir and release the drugs in a regulated manner. A study demonstrated the effectiveness of a chitosan-β-glycerophosphate hydrogel as a controlled release mechanism for fluoride in the gastrointestinal tract when taken orally. Low dosages of fluoride are known to promote the development of osteoblasts and decrease the likelihood of vertebral injuries in individuals with osteoporosis.¹⁴⁷

Evaluating the cytotoxicity of chitosan-based scaffolds

It is essential to evaluate the toxicity of chitosan-based scaffolds utilized for bone regeneration. This evaluation involves assessing many criteria, such as the integrity of cell membranes and the activity of mitochondria. The scaffold’s cellular milieu significantly influences its pro-regenerative capacity as a biomaterial. Several researchers have assessed the toxicity and biological compatibility of chitosan-based scaffolds, and the findings indicate that these scaffolds are non-toxic and biocompatible in both in vitro and in vivo settings. Gupta et al.¹⁴⁸ introduced dental pulp MSCs onto scaffolds made of both chitosan and chitosan integrated with vitamin D. The researchers then evaluated the cells metabolic activities after 72 h utilizing the colorimetric MTT test. The findings demonstrated the biocompatibility of both chitosan and chitosan scaffolds integrated with vitamin D, in comparison to the control group consisting of dental pulp mesenchymal stem cells (MSCs) in the growth medium. In a similar manner, Hu et al.¹⁴⁹ assessed the biocompatibility and ability to promote bone formation of scaffolds made from lanthanum phosphate and chitosan. When incubated with rBMSCs, these scaffolds did not exhibit any apparent toxicity or impact on cell shape. However, they did enhance the process of bone formation in a rat cranial injury model.

Conclusion and future prospects

Our understanding of osteoporosis has been steadily growing. However, the complex dynamics of bone activity and repair render simple methods rarely effective for their treatment. Consequently, certain targets have been established for the biomaterials employed in the treatment of various diseases. This article demonstrates the promise of chitosan scaffolds as therapeutic agents for bone treatment by providing a concise overview of the recent advancements in this field. Researchers employed chitosan, known for its sustainable characteristics and attributes, in combination with other polymers that are compatible with living organisms and can be naturally degradable. This combination led to the creation of films, nano/microparticles, and gels that can serve as drug-delivery systems for bone regeneration. Macromolecular engineering techniques can achieve precise modification of polymer properties, either by modifying polymers through (bio)conjugation or generating specific morphologies. As a result, these modified biomaterials will offer varying degrees of non-toxicity, biocompatibility, stability, target specificity, and biodegradability, hence serving as effective delivery methods for the management of osteoporosis. Whereas a wide range of different chitosan-based biomaterials have been investigated, it is apparent that this field demands significant attention to meet various requirements, such as biomaterial degradation, cytotoxicity, and their effects on both the environment and physiological functions. However, a few of these biomaterials are currently undergoing clinical trials. Hence, it is believed that the continued advancement of chitosan-based biomaterials would offer novel opportunities for effectively treating bone diseases.

Footnotes

Author contributions

YMW: Data gathering and organization; writing initial manuscript; JGT: Conception and design of the study; Review and finalization of the manuscript; Supervision and guidance of the work and finalization of the manuscript. All the authors read the final manuscript and agree to publish this work.

Data availability statement

Not Applicable. This is a review article and all relevant information is provided in the article.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval and consent to participate

Not applicable. This is a review paper and do not involve direct research on humans or animals.

Consent for publication

“Not applicable” as this manuscript does not contain data from any individual person.

ORCID iDs

Ya-Ming Wang

Jiang-Tao Shen

References

Chen

Zhong

, et al Roles of focal adhesion proteins in skeleton and diseases. Acta Pharm Sin B 2023; 13(3): 998–1013.

Chen

Geng

, et al The horizon of bone organoid: a perspective on construction and application. Bioact Mater 2022; 18: 15–25.

Grüneboom

Kling

Christiansen

, et al Next-generation imaging of the skeletal system and its blood supply. Nat Rev Rheumatol 2019; 15(9): 533–549.

Wawrzyniak

Balawender

. Structural and metabolic changes in bone. Animals 2022; 12(15): 1946.

Gao

Wang

, et al Bone marrow mesenchymal stromal cells: identification, classification, and differentiation. Frontiers Cell Dev Biol 2022; 9: 787118.

Manzini

Machado

Noritomi

, et al Advances in Bone tissue engineering: a fundamental review. J Biosci 2021; 46: 1–18.

Wang

You

Zhang

, et al Mechanical regulation of bone remodeling. Bone Res 2022; 10(1): 16.

Yin

Huang

, et al Stat3 signaling pathway: a future therapeutic target for bone-related diseases. Front Pharmacol 2022; 13: 897539.

Xue

Deng

, et al Recent advances in design of functional biocompatible hydrogels for bone tissue engineering. Adv Funct Mater 2021; 31(19): 2009432.

10.

Sobh

Abdalbary

Elnagar

, et al Secondary osteoporosis and metabolic bone diseases. J Clin Med 2022; 11(9): 2382.

11.

Nuti

Brandi

Checchia

, et al Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med 2019; 14: 85–102.

12.

Salamanna

Gambardella

Contartese

, et al Nano-based biomaterials as drug delivery systems against osteoporosis: a systematic review of preclinical and clinical evidence. Nanomaterials 2021; 11(2): 530.

13.

Xie

Zhang

Xiong

, et al Bench-to-bedside strategies for osteoporotic fracture: from osteoimmunology to mechanosensation. Bone Res 2019; 7(1): 25.

14.

Cui

Jackson

Wessler

, et al Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among women in China: a simulation projection model from 2020 to 2040. Arch Osteoporos 2021; 16: 1–10.

15.

Damiri

Gowda

Andra

, et al Chitosan nanocomposites as scaffolds for bone tissue regeneration. In: Swain

Biswal

(eds) Chitosan nanocomposites: bionanomechanical applications. Cham: Springer, 2023, pp.377–394.

16.

Damiri

Rahman

Zehravi

, et al MXene (Ti3C2Tx)-embedded nanocomposite hydrogels for biomedical applications: a review. Materials 2022; 15(5): 1666.

17.

Shahvalizadeh

Ahmadi

Davandeh

, et al Antimicrobial bio-nanocomposite films based on gelatin, tragacanth, and zinc oxide nanoparticles – microstructural, mechanical, thermo-physical, and barrier properties. Food Chem 2021; 354: 129492.

18.

Gholap

Rojekar

Kapare

, et al Chitosan scaffolds: expanding horizons in biomedical applications. Carbohydr Polym 2024; 323: 121394.

19.

Filippi

Born

Chaaban

, et al Natural polymeric scaffolds in bone regeneration. Front Bioeng Biotechnol 2020; 8: 474.

20.

Kumar

Vimal

Kumar

. Why chitosan? From properties to perspective of mucosal drug delivery. Int J Biol Macromol 2016; 91: 615–622.

21.

Lim

Hwang

Lee

. Intermolecular interactions of chitosan: degree of acetylation and molecular weight. Carbohydr Polym 2021; 259: 117782.

22.

Jiménez-Gómez

Cecilia

. Chitosan: a natural biopolymer with a wide and varied range of applications. Molecules 2020; 25(17): 3981.

23.

Bakshi

Selvakumar

Kadirvelu

, et al Chitosan as an environment friendly biomaterial—a review on recent modifications and applications. Int J Biol Macromol 2020; 150: 1072–1083.

24.

Wang

Xue

Mao

. Chitosan: structural modification, biological activity and application. Int J Biol Macromol 2020; 164: 4532–4546.

25.

Fernandez Corujo

Salum

Herrera

, et al Physically cross-linked biopolymer systems based on chitosan and hydroxycinnamic acids and their food preservation application studies. ACS Food Sci Technol 2022; 2(9): 1378–1400.

26.

Zaidi

Kim

Mathew

, et al Bone circuitry and interorgan skeletal crosstalk. eLife 2023; 12: e83142.

27.

Kim

Sultana

Sims

, et al FSH, bone, belly and brain. J Endocrinol 2024: 262(1): JOE-23-0377.

28.

Gera

Kuo

Gumerova

, et al FSH-blocking therapeutic for osteoporosis. eLife 2022; 11: e78022.

29.

Rojekar

Pallapati

Gimenez-Roig

, et al Development and biophysical characterization of a humanized FSH–blocking monoclonal antibody therapeutic formulated at an ultra-high concentration. eLife 2023; 12: e88898.

30.

Reid

. Anti-resorptive therapies for osteoporosis. Sem Cell Develop Biol 2008; 19(5): 473–478.

31.

Rachner

Khosla

Hofbauer

. Osteoporosis: now and the future. Lancet 2011; 377(9773): 1276–1287.

32.

Trubiani

Marconi

Pierdomenico

, et al Human oral stem cells, biomaterials and extracellular vesicles: a promising tool in bone tissue repair. Int J Mol Sci 2019; 20(20): 4987.

33.

Damiri

Rojekar

Bachra

, et al Polysaccharide-based nanogels for biomedical applications: a comprehensive review. J Drug Deliv Sci Technol 2023; 84: 104447.

34.

Arjmand

Sarvari

Alavi-Moghadam

, et al Prospect of stem cell therapy and regenerative medicine in osteoporosis. Front Endocrinol 2020; 11: 430.

35.

Charles

Aliprantis

. Osteoclasts: more than ‘bone eaters’. Trends Mol Med 2014; 20(8): 449–459.

36.

Jähn

Bonewald

. Bone cell biology: osteoclasts, osteoblasts, osteocytes. In: Glorieux

Pettifor

Jüppner

, et al (eds) Pediatric bone. San Diego, CA: Elsevier, 2012, pp.1–8.

37.

Zhang

Liesveld

Calvi

, et al The roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies. Bone Res 2023; 11(1): 15.

38.

Rajput

Wairkar

Gaud

. Nutraceuticals for better management of osteoporosis: an overview. J Funct Foods 2018; 47: 480–490.

39.

Patel

Wairkar

. Bone regeneration in osteoporosis: opportunities and challenges. Drug Deliv Transl Res 2023; 13(2): 419–432.

40.

Allen

Burr

. Bone modeling and remodeling. In: Burr

Allen

(eds) Basic and applied bone biology. San Diego, CA: Elsevier, 2014, pp.75–90.

41.

Eriksen

. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 2010; 11: 219–227.

42.

Pignolo

Law

Chandra

. Bone aging, cellular senescence, and osteoporosis. J Bone Miner Res Plus 2021; 5(4): e10488.

43.

Truesdell

Saunders

. Bone remodeling platforms: understanding the need for multicellular lab-on-a-chip systems and predictive agent-based models. Math Biosci Eng 2019; 17(2): 1233–1252.

44.

Mohammed

Shao

Wang

, et al Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Diseases 2016; 3(1): 11–40.

45.

Regan

Long

. Notch signaling and bone remodeling. Curr Osteoporos Rep 2013; 11: 126–129.

46.

Luo

Shang

Zhang

, et al Notch signaling in osteogenesis, osteoclastogenesis, and angiogenesis. Amer J Pathol 2019; 189(8): 1495–1500.

47.

Silvestro

Chiricosta

Gugliandolo

, et al Extracellular vesicles derived from human gingival mesenchymal stem cells: a transcriptomic analysis. Genes 2020; 11(2): 118.

48.

Gillman

Jayasuriya

. FDA-approved bone grafts and bone graft substitute devices in bone regeneration. Mater Sci Eng C 2021; 130: 112466.

49.

Schmidt-Bleek

Willie

Schwabe

, et al BMPs in bone regeneration: less is more effective, a paradigm-shift. Cytokine Growth Factor Rev 2016; 27: 141–148.

50.

Greenblatt

Shim

Bok

, et al The extracellular signal-regulated kinase mitogen-activated protein kinase pathway in osteoblasts. J Bone Metab 2022; 29(1): 1–15.

51.

Caplan

Correa

. PDGF in bone formation and regeneration: new insights into a novel mechanism involving MSCs. J Orthop Res 2011; 29(12): 1795–1803.

52.

Bolamperti

Villa

Rubinacci

. Bone remodeling: an operational process ensuring survival and bone mechanical competence. Bone Res 2022; 10(1): 48.

53.

Jin

Chen

. Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models. Bone Res 2014; 2(1): 1–24.

54.

Nicolaidou

Wong

Redpath

, et al Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation. PLoS One 2012; 7(7): e39871.

55.

Mediero

Kara

Wilder

, et al Adenosine A2A receptor ligation inhibits osteoclast formation. Amer J Pathol 2012; 180(2): 775–786.

56.

Ponzetti

Rucci

. Switching homes: how cancer moves to bone. Int J Mol Sci 2020; 21(11): 4124.

57.

Peake

Shah

Solan

. Bone metabolism and the receptor activator of nuclear factor-κB ligand (RANKL) pathway: a comprehensive review. Orthopaed Trauma 2021; 35(5): 297–304.

58.

Wang

, et al Dihydrotanshinone I attenuates estrogen-deficiency bone loss through RANKL-stimulated NF-κB, ERK and NFATc1 signaling pathways. Int Immunopharmacol 2023; 123: 110572.

59.

Paul

Edwards

Pepper

, et al Inhibitory-κB kinase (IKK) α and nuclear factor-κB (NFκB)-inducing kinase (NIK) as anti-cancer drug targets. Cells 2018; 7(10): 176.

60.

Mahmoud

Mohamed

Ali

, et al Nanomaterial-induced mesenchymal stem cell differentiation into osteoblast for counteracting bone resorption in the osteoporotic rats. Tissue Cell 2021; 73: 101645.

61.

Gao

Chen

, et al Progress of Wnt signaling pathway in osteoporosis. Biomolecules 2023; 13(3): 483.

62.

Lian

Stein

Javed

, et al Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord 2006; 7: 1–16.

63.

Kini

Nandeesh

. Physiology of bone formation, remodeling, and metabolism. In: Fogelman

Gnanasegaran

van der Wall

(eds) Radionuclide and hybrid bone imaging. Berlin: Springer, 2012, pp.29–57.

64.

Cao

Helder

Bravenboer

, et al

Is there a governing role of osteocytes in bone tissue regeneration?

Curr Osteoporos Rep 2020; 18(5): 541–550.

65.

Cassuto

Folestad

Göthlin

, et al The key role of proinflammatory cytokines, matrix proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients. Bone 2018; 107: 66–77.

66.

Han

You

Xing

, et al Paracrine and endocrine actions of bone—the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. Bone Res 2018; 6(1): 16.

67.

Narain

. Polymer science and nanotechnology: fundamentals and applications. Amsterdam: Elsevier, 2020.

68.

Chen

Zheng

, et al Bone targeted delivery of SDF-1 via alendronate functionalized nanoparticles in guiding stem cell migration. ACS Appl Mater Interf 2018; 10(28): 23700–23710.

69.

Yamashita

Katsumi

Hibino

, et al Development of PEGylated carboxylic acid-modified polyamidoamine dendrimers as bone-targeting carriers for the treatment of bone diseases. J Control Release 2017; 262: 10–17.

70.

Moradikhah

Doosti-Telgerd

Shabani

, et al Microfluidic fabrication of alendronate-loaded chitosan nanoparticles for enhanced osteogenic differentiation of stem cells. Life Sci 2020; 254: 117768.

71.

Saini

Fazil

Ali

, et al Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Drug Deliv 2015; 22(6): 823–836.

72.

Santhosh

Mukherjee

Anbu

, et al Improved treatment efficacy of risedronate functionalized chitosan nanoparticles in osteoporosis: formulation development, in vivo, and molecular modelling studies. J Microencapsul 2019; 36(4): 338–355.

73.

, et al Synergistic anti-inflammatory and osteogenic n-HA/resveratrol/chitosan composite microspheres for osteoporotic bone regeneration. Bioact Mater 2021; 6(5): 1255–1266.

74.

Zhang

Zhu

, et al Nanoparticles functionalized with stem cell secretome and CXCR4-overexpressing endothelial membrane for targeted osteoporosis therapy. J Nanobiotechnol 2022; 20(1): 35.

75.

Kotak

Devarajan

. Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT). Nanomed Nanotechnol Biol Med 2020; 24: 102153.

76.

Hoque

Shih

Zeng

, et al Bone targeting nanocarrier-assisted delivery of adenosine to combat osteoporotic bone loss. Biomaterials 2021; 273: 120819.

77.

Liu

Feng

Chen

, et al Ultrasmall superparamagnetic iron oxide labeled silk fibroin/hydroxyapatite multifunctional scaffold loaded with bone marrow-derived mesenchymal stem cells for bone regeneration. Front Bioeng Biotechnol 2020; 8: 697.

78.

Mora-Raimundo

Lozano

Manzano

, et al Nanoparticles to knockdown osteoporosis-related gene and promote osteogenic marker expression for osteoporosis treatment. ACS Nano 2019; 13(5): 5451–5464.

79.

Chen

, et al Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J 2019; 17: 661–674.

80.

Dong

Siegwart

Anderson

. Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev 2019; 144: 133–147.

81.

Cai

, et al Dual regulation of osteoclastogenesis and osteogenesis for osteoporosis therapy by iron oxide hydroxyapatite core/shell nanocomposites. Regen Biomater 2021; 8(5): rbab027.

82.

Lin

Chen

Chi

, et al In situ self-assembling micellar depots that can actively trap and passively release NO with long-lasting activity to reverse osteoporosis. Adv Mater 2018; 30(22): 1705605.

83.

Zeng

Yang

, et al Drug delivery and therapy strategies for osteoporosis intervention. Molecules 2023; 28(18): 6652.

84.

Nikzamir

Akbarzadeh

Panahi

. An overview on nanoparticles used in biomedicine and their cytotoxicity. J Drug Deliv Sci Technol 2021; 61: 102316.

85.

Bombin

ADJ

Dunne

McCarthy

. Electrospinning of natural polymers for the production of nanofibres for wound healing applications. Mater Sci Eng C 2020; 114: 110994.

86.

Zhao

Sun

, et al Biomedical applications of chitosan and its derivative nanoparticles. Polymers 2018; 10(4): 462.

87.

Ansari

Sadati

Mozafari

, et al Carbohydrate polymer-based nanoparticle application in drug delivery for CNS-related disorders. Eur Polym J 2020; 128: 109607.

88.

Aguilar

Zein

Harmouch

, et al Application of chitosan in bone and dental engineering. Molecules 2019; 24(16): 3009.

89.

Oryan

Sahvieh

. Effectiveness of chitosan scaffold in skin, bone and cartilage healing. Int J Biol Macromol 2017; 104: 1003–1011.

90.

Másson

. Antimicrobial properties of chitosan and its derivatives. In: Jayakumar

Prabaharan

(eds) Chitosan for biomaterials III: structure-property relationships. Berlin: Springer, 2021, pp.131–168.

91.

Ahmed

Ali

Sheikh

. A review on chitosan centred scaffolds and their applications in tissue engineering. Int J Biol Macromol 2018; 116: 849–862.

92.

Pattnaik

Nethala

Tripathi

, et al Chitosan scaffolds containing silicon dioxide and zirconia nano particles for bone tissue engineering. Int J Biol Macromol 2011; 49(5): 1167–1172.

93.

Venkatesan

Ryu

Sudha

, et al Preparation and characterization of chitosan–carbon nanotube scaffolds for bone tissue engineering. Int J Biol Macromol 2012; 50(2): 393–402.

94.

Thein-Han

Misra

. Biomimetic chitosan–nanohydroxyapatite composite scaffolds for bone tissue engineering. Acta Biomater 2009; 5(4): 1182–1197.

95.

Giger

Castagner

Leroux

. Biomedical applications of bisphosphonates. J Control Release 2013; 167(2): 175–188.

96.

Sandomierski

Adamska

Ratajczak

, et al Chitosan-zeolite scaffold as a potential biomaterial in the controlled release of drugs for osteoporosis. Int J Biol Macromol 2022; 223: 812–820.

97.

Hamedi

Moradi

Hudson

, et al Chitosan based hydrogels and their applications for drug delivery in wound dressings: a review. Carbohydr Polym 2018; 199: 445–460.

98.

Safdar

Omar

Arunagiri

, et al Potential of Chitosan and its derivatives for controlled drug release applications—a review. J Drug Deliv Sci Technol 2019; 49: 642–659.

99.

Almeida

Linares

Mora-Castaño

, et al 3D printed systems for colon-specific delivery of camptothecin-loaded chitosan micelles. Eur J Pharm Biopharm 2021; 167: 48–56.

100.

Luo

Han

Wang

, et al The thiolated chitosan: synthesis, gelling and antibacterial capability. Int J Biol Macromol 2019; 139: 521–530.

101.

Al Harthi

Alavi

Radwan

, et al Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer’s disease. Sci Rep 2019; 9(1): 9563.

102.

Cheng

Thapa

Remant

, et al Dual secured nano-melittin for the safe and effective eradication of cancer cells. J Mater Chem B 2015; 3(1): 25–29.

103.

Akopova

Demina

Cherkaev

, et al Solvent-free synthesis and characterization of allyl chitosan derivatives. RSC Adv 2019; 9(36): 20968–20975.

104.

Merchant

Taylor

Stapleton

, et al Engineering hydrophobically modified chitosan for enhancing the dispersion of respirable microparticles of levofloxacin. Eur J Pharm Biopharm 2014; 88(3): 816–829.

105.

Rajabi

Dohendou

Dekamin

. Synthesis of carboxymethyl chitosan and its derivatives using KI and/or ultrasonication. Chem Proc 2022; 12(1): 90.

106.

Mikušová

Mikuš

. Advances in chitosan-based nanoparticles for drug delivery. Int J Mol Sci 2021; 22(17): 9652.

107.

Dimassi

Tabary

Chai

, et al Sulfonated and sulfated chitosan derivatives for biomedical applications: a review. Carbohydr Polym 2018; 202: 382–396.

108.

Foster

LJR

Hook

, et al Chitosan as a biomaterial: influence of degree of deacetylation on its physiochemical, material and biological properties. PLoS One 2015; 10(8): e0135153.

109.

Saravanan

Leena

Selvamurugan

. Chitosan based biocomposite scaffolds for bone tissue engineering. Int J Biol Macromol 2016; 93: 1354–1365.

110.

Kumar

Jacob

. Techniques in scaffold fabrication process for tissue engineering applications: a review. J Appl Biol Biotechnol 2022; 10(3): 163–176.

111.

Wang

, et al

Production of chitosan scaffolds by lyophilization or electrospinning: which is better for peripheral nerve regeneration?

Neural Regen Res 2021; 16(6): 1093–1098.

112.

Lim

Lee

Shin

, et al Preparation of interconnected porous chitosan scaffolds by sodium acetate particulate leaching. J Biomater Sci Polym Ed 2011; 22(10): 1319–1329.

113.

Yuan

Strobbe

, et al 3D printed chemically and mechanically robust membrane by selective laser sintering for separation of oil/water and immiscible organic mixtures. Chem Eng J 2020; 385: 123816.

114.

Kopp

Smeets

Gosau

, et al Effect of process parameters on additive-free electrospinning of regenerated silk fibroin nonwovens. Bioact Mater 2020; 5(2): 241–252.

115.

Chocholata

Kulda

Babuska

. Fabrication of scaffolds for bone-tissue regeneration. Materials 2019; 12(4): 568.

116.

Perez-Puyana

Jiménez-Rosado

Romero

, et al Polymer-based scaffolds for soft-tissue engineering. Polymers 2020; 12(7): 1566.

117.

Pati

Gantelius

Svahn

. 3D bioprinting of tissue/organ models. Angew Chem Int Ed 2016; 55(15): 4650–4665.

118.

Yuan

Zhou

Chen

. Rapid prototyping technology and its application in bone tissue engineering. J Zhejiang Univ Sci B 2017; 18: 303–315.

119.

Creff

Courson

Mangeat

, et al Fabrication of 3D scaffolds reproducing intestinal epithelium topography by high-resolution 3D stereolithography. Biomaterials 2019; 221: 119404.

120.

Tao

Cheng

Tao

, et al Carboxymethyl chitosan/sodium alginate-based micron-fibers fabricated by emulsion electrospinning for periosteal tissue engineering. Mater Des 2020; 194: 108849.

121.

Trinca

Westin

da Silva

, et al Electrospun multilayer chitosan scaffolds as potential wound dressings for skin lesions. Eur Polym J 2017; 88: 161–170.

122.

Sun

Sui

, et al Composite mesoporous silica nanoparticle/chitosan nanofibers for bone tissue engineering. RSC Adv 2015; 5(23): 17541–17549.

123.

Kao

. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv 2010; 7(4): 429–444.

124.

Adepu

Ramakrishna

. Controlled drug delivery systems: current status and future directions. Molecules 2021; 26(19): 5905.

125.

Herdiana

Wathoni

Shamsuddin

, et al Drug release study of the chitosan-based nanoparticles. Heliyon 2022; 8(1): 1–16.

126.

Saber-Samandari

. Biocompatible nanocomposite scaffolds based on copolymer-grafted chitosan for bone tissue engineering with drug delivery capability. Mater Sci Eng C 2017; 75: 721–732.

127.

Ata

Rasool

Islam

, et al Loading of Cefixime to pH sensitive chitosan based hydrogel and investigation of controlled release kinetics. Int J Biol Macromol 2020; 155: 1236–1244.

128.

Vermonden

Censi

Hennink

. Hydrogels for protein delivery. Chem Rev 2012; 112(5): 2853–2888.

129.

Gull

Khan

Butt

, et al In vitro study of chitosan-based multi-responsive hydrogels as drug release vehicles: a preclinical study. RSC Adv 2019; 9(53): 31078–31091.

130.

Fonseca-Santos

Chorilli

. An overview of carboxymethyl derivatives of chitosan: their use as biomaterials and drug delivery systems. Mater Sci Eng C 2017; 77: 1349–1362.

131.

Gentile

Nandagiri

Daly

, et al Localised controlled release of simvastatin from porous chitosan–gelatin scaffolds engrafted with simvastatin loaded PLGA-microparticles for bone tissue engineering application. Mater Sci Eng C 2016; 59: 249–257.

132.

Song

, et al Mesoporous silica nanoparticles for stimuli-responsive controlled drug delivery: advances, challenges, and outlook. Int J Nanomedicine 2017; 12: 87–110.

133.

Zhao

Qazvini

Sadati

, et al A pH-triggered, self-assembled, and bioprintable hybrid hydrogel scaffold for mesenchymal stem cell based bone tissue engineering. ACS Appl Mater Interf 2019; 11(9): 8749–8762.

134.

Wen

Jung

. Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges. AAPS J 2015; 17: 1327–1340.

135.

De Campos

Sánchez

Alonso

MAJ

. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Appl Cyclosporin A Int J Pharm 2001; 224(1–2): 159–168.

136.

Mouriño

Boccaccini

. Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds. J Royal Soc Interf 2010; 7(43): 209–227.

137.

Cosman

. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Curr Osteoporos Rep 2014; 12: 385–395.

138.

Feng

Wang

Jiang

, et al Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: in vitro and in vivo evaluation. Int J Pharm 2013; 457(1): 158–167.

139.

Kim

Jang

Son

, et al Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability. Eur J Pharm Sci 2016; 82: 45–51.

140.

Cardozo

Karatza

Karalis

. Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. Osteoporos Int 2021; 32(11): 2313–2321.

141.

Tian

, et al Chitosan-based biomaterial scaffolds for the repair of infected bone defects. Front Bioeng Biotechnol 2022; 10: 899760.

142.

Jing

Tan

, et al Alendronate-decorated nanoparticles as bone-targeted alendronate carriers for potential osteoporosis treatment. ACS Appl Bio Mater 2021; 4(6): 4907–4916.

143.

Lei

Liu

, et al Reconstruction of large-scale defects with a novel hybrid scaffold made from Poly(L-lactic acid)/Nanohydroxyapatite/Alendronate-loaded chitosan microsphere: in vitro and in vivo studies. Sci Rep 2017;7(1): 359.

144.

Abdel-Salam

Elkheshen

Mahmoud

, et al In-situ forming chitosan implant-loaded with raloxifene hydrochloride and bioactive glass nanoparticles for treatment of bone injuries: formulation and biological evaluation in animal model. Int J Pharm 2020; 580: 119213.

145.

Zhang

Rong

Liang

, et al Chitosan modified with PAP as a promising delivery system for melatonin in the treatment of osteoporosis: targeting the divalent metal transporter. J Biol Eng 2024; 18(1): 27.

146.

Pathak

Sahu

Begum

, et al Formulation and assessment of penetration potential of Risedronate chitosan nanoparticles loaded transdermal gel in the management of osteoporosis: in vitro and ex vivo screening. Carbohydr Polym Technol Appl 2024; 7: 100440.

147.

Zhou

Jiang

Cao

, et al Glycerophosphate-based chitosan thermosensitive hydrogels and their biomedical applications. Carbohydr Polym 2015; 117: 524–536.

148.

Gupta

Kheur

Badhe

, et al Assessing the potential use of chitosan scaffolds for the sustained localized delivery of vitamin D. Saudi J Biol Sci 2021; 28(4): 2210–2215.

149.

Zhao

Liu

, et al Lanthanum phosphate/chitosan scaffolds enhance cytocompatibility and osteogenic efficiency via the Wnt/β-catenin pathway. J Nanobiotechnol 2018; 16: 1–13.

Chitosan-based promising scaffolds for the construction of tailored nanosystems against osteoporosis: Current status and future prospects

Abstract

Keywords

Introduction

Osteoporosis

Bone remodeling process

Role of bone cells in bone remodeling

Nanomaterials in treatment of osteoporosis

Polymers in osteoporosis management

Chitosan

Synthesis of chitosan scaffolds

Mechanism underlying the release of drugs from chitosan-based scaffolds

Osteoporosis treatment using chitosan-based scaffolds

Evaluating the cytotoxicity of chitosan-based scaffolds

Conclusion and future prospects

Footnotes

Author contributions

Data availability statement

Declaration of conflicting interests

Funding

Ethical approval and consent to participate

Consent for publication

ORCID iDs

References